Probiotic Intake and Perimenopausal Psychological Assessments

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age45-60
SponsorUniversity of Oxford

About this trial

Recent evidence suggests multi-strain probiotics containing Lactobacillus rhamnosus and Bifidobacterium longum have been found to enhance emotional processing and reduce salience to negative cues in studies involving people with mood disorders, as well as improve cognitive functions, such as memory and concentration, in healthy participants. By administering computer-based tasks, questionnaires and checking biological measures (cortisol, immune markers, blood metabolites, gut microbiota) using blood and faecal samples, this experimental medicine study aims to investigate whether a probiotic supplement has an effect on emotional processing and cognition in perimenopausal women. We also aim to study changes in gut bacteria from stool samples before and after taking the supplement to see if any microbiome changes are associated with any effects in emotional processing, cognitive function, and biological markers.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female at birth

You are aged 45-60 years and in perimenopause (determined by changes in menstrual bleeding patterns (such as changes in cycle length of 7 days or longer in either direction from what is normal for you), AND vasomotor symptoms (e.g., hot flushes and sweats) AND mild to moderate mood or cognitive disturbances, or joint and muscle pain over the previous 12 months)

You are willing and able to give informed consent for participation in the study

You are sufficiently fluent in English to understand and complete tasks

Disqualifiers

Currently receive or seek treatment for any mental health condition

Have a BMI >=30 OR <=18.5

Have lost or gained more than 10% of body weight in a short period (e.g., 6 months), as this can affect mood and cognition

Currently using hormonal contraception or have used hormonal contraception in the last 6 months

Trial design

Design model

Parallel

Treatments tested in this trial

  • Multi-strain probiotic

    Dietary supplement

    A commercially available probiotic known to support gut health and is generally well-tolerated.

  • Placebo

    Dietary supplement

    A microcrystalline cellulose-based capsule.

Treatment groups

106 Participants
are divided into 2 treatment groups
Group A: Patient GroupPlacebo comparator 1 intervention
Group B: Interventional/TreatmentExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Facial Expression Recognition Task (FERT)

Accuracy, reaction time and misclassifications on the FERT compared between probiotic and placebo groups.

Time frame
End of the 60-day intervention

Secondary outcomes

1

Emotional Categorisation Task

Accuracy and reaction time performance on emotional word categorization task compared between probiotic and placebo groups.

Time frame
End of the 60-day intervention
2

Emotional word recall/recognition task

Performance on emotional word recall (hits and false alarms) and recogntion (hits, false alarms and reaction time) compared between probiotic and placebo groups

Time frame
End of the 60-day intervention
3

Digit Span Task

Maximum span length compared between probiotic and placebo groups

Time frame
End of the 60-day intervention
4

Emotional Go/No-Go (EGNG)

Cognitive control and inhibitory control assessed using the EGNG task, including commission errors, omission errors, and reaction time to emotionally valenced stimuli. Performance will be compared between probiotic and placebo groups at post-intervention.

Time frame
Post-intervention (end of 60-day intervention)

Other outcomes

1

Subjective measures of affective state

Questionnaire measures of affect (PANAS) compared between placebo and probiotic groups

Time frame
Baseline, Day 14, Day 30, Day 44, Day 60
2

Subjective measures of mood

Questionnaire measures of mood (PANAS) compared between placebo and probiotic groups

Time frame
Baseline, Day 14, Day 30, Day 44, Day 60
3

Subjective measures of menopausal symptom severity

Questionnaire measures of menopausal symptom severity (MRS) compared between placebo and probiotic groups

Time frame
Baseline, Day 14, Day 30, Day 44, Day 60
4

Subjective measures of cognitive state

Questionnaire measures of subjective cognitive difficulties (PDQ) compared between placebo and probiotic groups

Time frame
Baseline, Day 14, Day 30, Day 44, Day 60

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Oxford

Lead sponsor

ADM Protexin

Collaborator